Table 2.
Characteristics of the study population at 12 months evaluation according to events.
| 12-Months Evaluation | All (n = 606) |
Event (n = 42) |
No Event (n = 564) |
p-Value |
|---|---|---|---|---|
| Post-therapy Tg (ng/mL) | 4 ± 11 | 17 ± 29 | 4 ± 14 | <0.001 |
| Undetectable Tg/AbTg, n (%) | 97 (31) | 6 (16) | 91 (32) | <0.05 |
| Detectable Tg, n (%) | 342 (56) | 30 (71) | 312 (55) | <0.01 |
| Detectable AbTg, n (%) | 38 (6) | 5 (12) | 33 (6) | 0.12 |
| Normal US, n (%) | 572 (94) | 35 (83) | 537 (95) | <0.001 |
| Abnormal US, n (%) | 34 (6) | 7 (17) | 27 (5) | <0.001 |
| Uptake at diagnostic WBS, n (%) | 77 (13) | 29 (70) | 48 (9) | <0.001 |
| Thyroid bed, n (%) | 65 (11) | 19 (45) | 46 (8) | <0.001 |
| Suspicious for lymph nodes, n (%) | 2 (0.5) | 2 (5) | 2 (0.5) | <0.001 |
| Extra-neck uptake, n (%) | 8 (1) | 8 (19) | 0 | - |
Data are presented as mean ± SD or number and percentage (%). Tg (thyroglobulin), WBS (whole body scan), US (ultrasound).